查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1285776

小细胞肺癌（SCLC）治疗市场（治疗类型：靶向治疗，免疫治疗，和化学治疗；给药途径：口服、肠外和其他） - 2023-2031年全球行业分析、规模、份额、增长、趋势和预测

Small Cell Lung Cancer (SCLC) Therapeutics Market (Therapy Type: Targeted Therapy, Immunotherapy, & Chemotherapy; Route of Administration: Oral, Parenteral, & Others) - Global Industry Analysis, Size, Share, Growth, Trends, & Forecast, 2023-2031
出版日期: | 出版商: Transparency Market Research | 英文 201 Pages | 商品交期: 2-10个工作天内

价格

小细胞肺癌（SCLC）治疗药物市场 - 报告范围

TMR关于全球小细胞肺癌（SCLC）治疗剂市场的报告研究了过去以及当前的增长趋势和机会，以获得对2023年至2031年预测期间市场指标的宝贵见解。报告提供了2017-2031年全球小细胞肺癌（SCLC）治疗药物市场的收入，考虑到2023年为基准年，2031年为预测年。报告还提供了2023年至2031年全球小细胞肺癌（SCLC）治疗药物市场的复合年增长率（CAGR %）。

该报告是在广泛的研究后编写的。一级研究涉及大部分的研究工作，其中分析师与关键意见领袖、行业领袖和意见制造者进行了访谈。二级研究包括参考主要参与者的产品资料、年度报告、新闻稿和相关文件，以了解等离子体材料市场。

该报告深入研究了全球等离子体材料市场的竞争格局。在全球小细胞肺癌（SCLC）治疗市场运作的主要参与者已被确定，其中每一个都在各种属性方面进行了分析。公司概况、财务状况、近期发展和SWOT是本报告对全球小细胞肺癌（SCLC）治疗剂市场参与者的属性分析。

目录

第一章：前言

  • 市场定义和范围
  • 市场细分
  • 主要研究目标
  • 研究重点

第二章：假设和研究方法

第三章：执行摘要：全球市场

第四章：市场概述

  • 简介
    • 治疗类型的定义
    • 行业演变/发展
  • 概述
  • 市场动态
    • 驱动力
    • 限制因素
    • 机会
  • 全球市场分析和预测，2017-2031年

第五章：关键洞察力

  • 管线分析
  • 全球及主要国家的疾病流行率和发病率
  • 关键的行业事件
  • COVID-19对行业的影响

第六章：全球市场分析和预测：按治疗类型划分

  • 介绍和定义
  • 主要研究结果/发展情况
  • 市场价值预测：按治疗类型，2017-2031年
    • 靶向治疗
    • 免疫疗法
    • 化疗
  • 市场吸引力：按治疗类型划分

第七章 ：全球市场分析与预测：按药物类型划分

  • 介绍和定义
  • 主要研究结果/发展情况
  • 市场价值预测：按药物类型，2017-2031年
    • Atezolizumab
    • 杜瓦卢单抗
    • 鲁滨逊(Lurbinectedin)
    • Pembrolizumab
    • 伊托泊苷
    • 甲氨蝶呤
    • 托泊替康
    • 其他药物
  • 市场吸引力：按药物类型

第八章：全球市场分析与预测：按给药途径分类

  • 介绍和定义
  • 主要研究结果/发展情况
  • 市场价值预测：按给药途径分类，2017-2031年
    • 口服
    • 肠外
    • 其他途径
  • 市场吸引力：按给药途径分类

第九章：全球市场分析与预测：按分销渠道分类

  • 介绍和定义
  • 主要研究结果/发展情况
  • 市场价值预测：按分销渠道划分，2017-2031年
    • 医院药房
    • 零售药店
    • 网上药店
  • 市场吸引力：按分销渠道划分

第十章：全球市场分析与预测：按地区划分

  • 主要研究结果
  • 市场价值预测：按地区
    • 北美洲
    • 欧洲
    • 亚太地区
    • 拉丁美洲
    • 中东和非洲
  • 市场吸引力：按国家/地区

第11章 ：北美洲市场分析与预测

  • 简介
    • 主要发现
  • 市场价值预测：按治疗类型，2017-2031年
    • 靶向治疗
    • 免疫疗法
    • 化疗
  • 市场价值预测：按药物类型，2017 - 2031年
    • Atezolizumab
    • 杜瓦卢单抗
    • 鲁滨逊(Lurbinectedin)
    • Pembrolizumab
    • 伊托泊苷
    • 甲氨蝶呤
    • 托泊替康
    • 其他药物
  • 市场价值预测：按给药途径，2017 - 2031年
    • 口服
    • 肠外
    • 其他途径
  • 市场价值预测：按分销渠道划分，2017 - 2031年
    • 医院药房
    • 零售药店
    • 网上药店
  • 市场价值预测：按国家划分，2017 - 2031年
    • 美国
    • 加拿大
  • 市场吸引力分析
    • 按治疗类型
    • 按药物类型
    • 按给药途径分类
    • 按分销渠道分类
    • 按国家分类

第12章 ：欧洲市场分析和预测

  • 简介
    • 主要发现
  • 市场价值预测：按治疗类型，2017-2031年
    • 靶向治疗
    • 免疫疗法
    • 化疗
  • 市场价值预测：按药物类型，2017 - 2031年
    • Atezolizumab
    • 杜瓦卢单抗
    • 鲁滨逊(Lurbinectedin)
    • Pembrolizumab
    • 伊托泊苷
    • 甲氨蝶呤
    • 托泊替康
    • 其他药物
  • 市场价值预测：按给药途径，2017 - 2031年
    • 口服
    • 肠外
    • 其他途径
  • 市场价值预测：按分销渠道划分，2017 - 2031年
    • 医院药房
    • 零售药店
    • 网上药店
  • 市场价值预测：按国家划分，2017 - 2031年
    • 德国
    • 英国
    • 法国
    • 西班牙
    • 意大利
    • 欧洲其他地区
  • 市场吸引力分析
    • 按治疗类型
    • 按药物类型分类
    • 按给药途径分类
    • 按分销渠道分类
    • 按国家分类

第13章 ：亚太地区市场分析和预测

  • 介紹
    • 主要发现
  • 市场价值预测：按治疗类型，2017-2031年
    • 靶向治疗
    • 免疫疗法
    • 化疗
  • 市场价值预测：按药物类型，2017 - 2031年
    • Atezolizumab
    • 杜瓦卢单抗
    • 鲁滨逊(Lurbinectedin)
    • Pembrolizumab
    • 伊托泊苷
    • 甲氨蝶呤
    • 托泊替康
    • 其他药物
  • 市场价值预测：按给药途径，2017 - 2031年
    • 口服
    • 肠外
    • 其他途径
  • 市场价值预测：按分销渠道划分，2017 - 2031年
    • 医院药房
    • 零售药店
    • 网上药店
  • 市场价值预测：按国家划分，2017 - 2031年
    • 中国
    • 日本
    • 印度
    • 澳大利亚和新西兰
    • 亚太其他地区
  • 市场吸引力分析
    • 按治疗类型
    • 按药物类型
    • 按给药途径分类
    • 按分销渠道
    • 按国家分类

第十四章 ：拉美市场分析和预测

  • 简介
    • 主要发现
  • 市场价值预测：按治疗类型，2017-2031年
    • 靶向治疗
    • 免疫疗法
    • 化疗
  • 市场价值预测：按药物类型，2017 - 2031年
    • Atezolizumab
    • 杜瓦卢单抗
    • 鲁滨逊(Lurbinectedin)
    • Pembrolizumab
    • 伊托泊苷
    • 甲氨蝶呤
    • 托泊替康
    • 其他药物
  • 市场价值预测：按给药途径，2017 - 2031年
    • 口服
    • 肠外
    • 其他途径
  • 市场价值预测：按分销渠道，2017 - 2031年
    • 医院药房
    • 零售药店
    • 网上药店
  • 市场价值预测：按国家划分，2017 - 2031年
    • 巴西
    • 墨西哥
    • 拉美其他地区
  • 市场吸引力分析
    • 按治疗类型
    • 按药物类型
    • 按给药途径分类
    • 按分销渠道
    • 按国家分类

第15章 ：中东和非洲市场分析和预测

  • 简介
    • 主要发现
  • 市场价值预测：按治疗类型，2017-2031年
    • 靶向治疗
    • 免疫疗法
    • 化疗
  • 市场价值预测：按药物类型，2017 - 2031年
    • Atezolizumab
    • 杜瓦卢单抗
    • 鲁滨逊(Lurbinectedin)
    • Pembrolizumab
    • 伊托泊苷
    • 甲氨蝶呤
    • 托泊替康
    • 其他药物
  • 市场价值预测：按给药途径，2017 - 2031年
    • 口服
    • 肠外
    • 其他途径
  • 市场价值预测：按分销渠道，2017 - 2031年
    • 医院药房
    • 零售药店
    • 网上药店
  • 市场价值预测：按国家划分，2017 - 2031年
    • 海湾合作委员会国家
    • 南非
    • 中东和非洲其他地区
  • 市场吸引力分析
    • 按治疗类型
    • 按药物类型分类
    • 按给药途径分类
    • 按分销渠道
    • 按国家分类

第16章 ：竞争格局

  • 市场参与者 - 竞争矩阵（按公司的层级和规模分类）
  • 按公司分类的市场占有率分析（2021年）
  • 公司简介
    • AstraZeneca plc
    • Dr. Reddy's Laboratories, Inc.
    • F. Hoffmann La-Roche Ltd.
    • GSK plc
    • Jazz Pharmaceuticals plc
    • Merck & Co., Inc.
    • Novartis AG
    • Pfizer Inc.
Product Code: TMRGL49311

Small Cell Lung Cancer (SCLC) Therapeutics Market - Scope of Report

TMR's report on the global Small Cell Lung Cancer (SCLC) Therapeutics Market studies the past as well as the current growth trends and opportunities to gain valuable insights of the indicators of the market during the forecast period from 2023 to 2031. The report provides revenue of the global Small Cell Lung Cancer (SCLC) Therapeutics Market for the period 2017-2031, considering 2023 as the base year and 2031 as the forecast year. The report also provides the compound annual growth rate (CAGR %) of the global Small Cell Lung Cancer (SCLC) Therapeutics Market from 2023 to 2031.

The report has been prepared after an extensive research. Primary research involved bulk of the research efforts, wherein analysts carried out interviews with key opinion leaders, industry leaders, and opinion makers. Secondary research involved referring to key players' product literature, annual reports, press releases, and relevant documents to understand the Small Cell Lung Cancer (SCLC) Therapeutics market.

Secondary research also included Internet sources, statistical data from government agencies, websites, and trade associations. Analysts employed a combination of top-down and bottom-up approaches to study various attributes of the global Small Cell Lung Cancer (SCLC) Therapeutics market.

The report includes an elaborate executive summary, along with a snapshot of the growth behavior of various segments included in the scope of the study. Moreover, the report throws light on the changing competitive dynamics in the global Small Cell Lung Cancer (SCLC) Therapeutics market. These serve as valuable tools for existing market players as well as for entities interested in participating in the global Small Cell Lung Cancer (SCLC) Therapeutics market.

The report delves into the competitive landscape of the global Small Cell Lung Cancer (SCLC) Therapeutics market. Key players operating in the global Small Cell Lung Cancer (SCLC) Therapeutics Market have been identified and each one of these has been profiled in terms of various attributes. Company overview, financial standings, recent developments, and SWOT are the attributes of players in the global Small Cell Lung Cancer (SCLC) Therapeutics Market profiled in this report.

Key Questions Answered in Global Small Cell Lung Cancer (SCLC) Therapeutics Market Report:

  • What is the sales/revenue generated by Small Cell Lung Cancer (SCLC) Therapeutics across all regions during the forecast period?
  • What are the opportunities in the global Small Cell Lung Cancer (SCLC) Therapeutics market?
  • What are the major drivers, restraints, opportunities, and threats in the market?
  • Which regional market is set to expand at the fastest CAGR during the forecast period?
  • Which segment is expected to generate the highest revenue globally in 2031?
  • Which segment is projected to expand at the highest CAGR during the forecast period?
  • What are the market positions of different companies operating in the global market?

Small Cell Lung Cancer (SCLC) Therapeutics Market - Research Objectives and Research Approach

The comprehensive report on the global Small Cell Lung Cancer (SCLC) Therapeutics Market begins with an overview, followed by the scope and objectives of the study. The report provides detailed explanation of the objectives behind this study and key vendors and distributors operating in the market and regulatory scenario for approval of products.

For reading comprehensibility, the report has been compiled in a chapter-wise layout, with each section divided into smaller ones. The report comprises an exhaustive collection of graphs and tables that are appropriately interspersed. Pictorial representation of actual and projected values of key segments is visually appealing to readers. This also allows comparison of the market shares of key segments in the past and at the end of the forecast period.

The report analyzes the global Small Cell Lung Cancer (SCLC) Therapeutics Market in terms of product, end-user, and region. Key segments under each criterion have been studied at length, and the market share for each of these at the end of 2031 has been provided. Such valuable insights enable market stakeholders in making informed business decisions for investment in the global Small Cell Lung Cancer (SCLC) Therapeutics market.

Table of Contents

1. Preface

  • 1.1. Market Definition and Scope
  • 1.2. Market Segmentation
  • 1.3. Key Research Objectives
  • 1.4. Research Highlights

2. Assumptions and Research Methodology

3. Executive Summary: Global Small Cell Lung Cancer (SCLC) Therapeutics Market

4. Market Overview

  • 4.1. Introduction
    • 4.1.1. Therapy Type Definition
    • 4.1.2. Industry Evolution/Developments
  • 4.2. Overview
  • 4.3. Market Dynamics
    • 4.3.1. Drivers
    • 4.3.2. Restraints
    • 4.3.3. Opportunities
  • 4.4. Global Small Cell Lung Cancer (SCLC) Therapeutics Market Analysis and Forecast, 2017 - 2031

5. Key Insights

  • 5.1. Pipeline Analysis
  • 5.2. Disease Prevalence & Incidence Rate globally with key countries
  • 5.3. Key Industry Events
  • 5.4. COVID-19 Impact on Industry

6. Global Small Cell Lung Cancer (SCLC) Therapeutics Market Analysis and Forecast, by Therapy Type

  • 6.1. Introduction & Definition
  • 6.2. Key Findings / Developments
  • 6.3. Market Value Forecast, by Therapy Type, 2017 - 2031
    • 6.3.1. Targeted Therapy
    • 6.3.2. Immunotherapy
    • 6.3.3. Chemotherapy
  • 6.4. Market Attractiveness, by Therapy Type

7. Global Small Cell Lung Cancer (SCLC) Therapeutics Market Analysis and Forecast, by Drug Type

  • 7.1. Introduction & Definition
  • 7.2. Key Findings / Developments
  • 7.3. Market Value Forecast, by Drug Type, 2017 - 2031
    • 7.3.1. Atezolizumab
    • 7.3.2. Durvalumab
    • 7.3.3. Lurbinectedin
    • 7.3.4. Pembrolizumab
    • 7.3.5. Etoposide
    • 7.3.6. Methotrexate
    • 7.3.7. Topotecan
    • 7.3.8. Others
  • 7.4. Market Attractiveness, by Drug Type

8. Global Small Cell Lung Cancer (SCLC) Therapeutics Market Analysis and Forecast, by Route of Administration

  • 8.1. Introduction & Definition
  • 8.2. Key Findings / Developments
  • 8.3. Market Value Forecast, by Route of Administration, 2017 - 2031
    • 8.3.1. Oral
    • 8.3.2. Parenteral
    • 8.3.3. Others
  • 8.4. Market Attractiveness, by Route of Administration

9. Global Small Cell Lung Cancer (SCLC) Therapeutics Market Analysis and Forecast, by Distribution Channel

  • 9.1. Introduction & Definition
  • 9.2. Key Findings / Developments
  • 9.3. Market Value Forecast, by Distribution Channel, 2017 - 2031
    • 9.3.1. Hospital Pharmacies
    • 9.3.2. Retail Pharmacies
    • 9.3.3. Online Pharmacies
  • 9.4. Market Attractiveness, by Distribution Channel

10. Global Small Cell Lung Cancer (SCLC) Therapeutics Market Analysis and Forecast, by Region

  • 10.1. Key Findings
  • 10.2. Market Value Forecast, by Region
    • 10.2.1. North America
    • 10.2.2. Europe
    • 10.2.3. Asia Pacific
    • 10.2.4. Latin America
    • 10.2.5. Middle East & Africa
  • 10.3. Market Attractiveness, by Country/Region

11. North America Small Cell Lung Cancer (SCLC) Therapeutics Market Analysis and Forecast

  • 11.1. Introduction
    • 11.1.1. Key Findings
  • 11.2. Market Value Forecast, by Therapy Type, 2017 - 2031
    • 11.2.1. Targeted Therapy
    • 11.2.2. Immunotherapy
    • 11.2.3. Chemotherapy
  • 11.3. Market Value Forecast, by Drug Type, 2017 - 2031
    • 11.3.1. Atezolizumab
    • 11.3.2. Durvalumab
    • 11.3.3. Lurbinectedin
    • 11.3.4. Pembrolizumab
    • 11.3.5. Etoposide
    • 11.3.6. Methotrexate
    • 11.3.7. Topotecan
    • 11.3.8. Others
  • 11.4. Market Value Forecast, by Route of Administration, 2017 - 2031
    • 11.4.1. Oral
    • 11.4.2. Parenteral
    • 11.4.3. Others
  • 11.5. Market Value Forecast, by Distribution Channel, 2017 - 2031
    • 11.5.1. Hospital Pharmacies
    • 11.5.2. Retail Pharmacies
    • 11.5.3. Online Pharmacies
  • 11.6. Market Value Forecast, by Country, 2017 - 2031
    • 11.6.1. U.S.
    • 11.6.2. Canada
  • 11.7. Market Attractiveness Analysis
    • 11.7.1. By Therapy Type
    • 11.7.2. By Drug Type
    • 11.7.3. By Route of Administration
    • 11.7.4. By Distribution Channel
    • 11.7.5. By Country

12. Europe Small Cell Lung Cancer (SCLC) Therapeutics Market Analysis and Forecast

  • 12.1. Introduction
    • 12.1.1. Key Findings
  • 12.2. Market Value Forecast, by Therapy Type, 2017 - 2031
    • 12.2.1. Targeted Therapy
    • 12.2.2. Immunotherapy
    • 12.2.3. Chemotherapy
  • 12.3. Market Value Forecast, by Drug Type, 2017 - 2031
    • 12.3.1. Atezolizumab
    • 12.3.2. Durvalumab
    • 12.3.3. Lurbinectedin
    • 12.3.4. Pembrolizumab
    • 12.3.5. Etoposide
    • 12.3.6. Methotrexate
    • 12.3.7. Topotecan
    • 12.3.8. Others
  • 12.4. Market Value Forecast, by Route of Administration, 2017 - 2031
    • 12.4.1. Oral
    • 12.4.2. Parenteral
    • 12.4.3. Others
  • 12.5. Market Value Forecast, by Distribution Channel, 2017 - 2031
    • 12.5.1. Hospital Pharmacies
    • 12.5.2. Retail Pharmacies
    • 12.5.3. Online Pharmacies
  • 12.6. Market Value Forecast, by Country, 2017 - 2031
    • 12.6.1. Germany
    • 12.6.2. U.K.
    • 12.6.3. France
    • 12.6.4. Spain
    • 12.6.5. Italy
    • 12.6.6. Rest of Europe
  • 12.7. Market Attractiveness Analysis
    • 12.7.1. By Therapy Type
    • 12.7.2. By Drug Type
    • 12.7.3. By Route of Administration
    • 12.7.4. By Distribution Channel
    • 12.7.5. By Country

13. Asia Pacific Small Cell Lung Cancer (SCLC) Therapeutics Market Analysis and Forecast

  • 13.1. Introduction
    • 13.1.1. Key Findings
  • 13.2. Market Value Forecast, by Therapy Type, 2017 - 2031
    • 13.2.1. Targeted Therapy
    • 13.2.2. Immunotherapy
    • 13.2.3. Chemotherapy
  • 13.3. Market Value Forecast, by Drug Type, 2017 - 2031
    • 13.3.1. Atezolizumab
    • 13.3.2. Durvalumab
    • 13.3.3. Lurbinectedin
    • 13.3.4. Pembrolizumab
    • 13.3.5. Etoposide
    • 13.3.6. Methotrexate
    • 13.3.7. Topotecan
    • 13.3.8. Others
  • 13.4. Market Value Forecast, by Route of Administration, 2017 - 2031
    • 13.4.1. Oral
    • 13.4.2. Parenteral
    • 13.4.3. Others
  • 13.5. Market Value Forecast, by Distribution Channel, 2017 - 2031
    • 13.5.1. Hospital Pharmacies
    • 13.5.2. Retail Pharmacies
    • 13.5.3. Online Pharmacies
  • 13.6. Market Value Forecast, by Country, 2017 - 2031
    • 13.6.1. China
    • 13.6.2. Japan
    • 13.6.3. India
    • 13.6.4. Australia & New Zealand
    • 13.6.5. Rest of Asia Pacific
  • 13.7. Market Attractiveness Analysis
    • 13.7.1. By Therapy Type
    • 13.7.2. By Drug Type
    • 13.7.3. By Route of Administration
    • 13.7.4. By Distribution Channel
    • 13.7.5. By Country

14. Latin America Small Cell Lung Cancer (SCLC) Therapeutics Market Analysis and Forecast

  • 14.1. Introduction
    • 14.1.1. Key Findings
  • 14.2. Market Value Forecast, by Therapy Type, 2017 - 2031
    • 14.2.1. Targeted Therapy
    • 14.2.2. Immunotherapy
    • 14.2.3. Chemotherapy
  • 14.3. Market Value Forecast, by Drug Type, 2017 - 2031
    • 14.3.1. Atezolizumab
    • 14.3.2. Durvalumab
    • 14.3.3. Lurbinectedin
    • 14.3.4. Pembrolizumab
    • 14.3.5. Etoposide
    • 14.3.6. Methotrexate
    • 14.3.7. Topotecan
    • 14.3.8. Others
  • 14.4. Market Value Forecast, by Route of Administration, 2017 - 2031
    • 14.4.1. Oral
    • 14.4.2. Parenteral
    • 14.4.3. Others
  • 14.5. Market Value Forecast, by Distribution Channel, 2017 - 2031
    • 14.5.1. Hospital Pharmacies
    • 14.5.2. Retail Pharmacies
    • 14.5.3. Online Pharmacies
  • 14.6. Market Value Forecast, by Country, 2017 - 2031
    • 14.6.1. Brazil
    • 14.6.2. Mexico
    • 14.6.3. Rest of Latin America
  • 14.7. Market Attractiveness Analysis
    • 14.7.1. By Therapy Type
    • 14.7.2. By Drug Type
    • 14.7.3. By Route of Administration
    • 14.7.4. By Distribution Channel
    • 14.7.5. By Country

15. Middle East & Africa Small Cell Lung Cancer (SCLC) Therapeutics Market Analysis and Forecast

  • 15.1. Introduction
    • 15.1.1. Key Findings
  • 15.2. Market Value Forecast, by Therapy Type, 2017 - 2031
    • 15.2.1. Targeted Therapy
    • 15.2.2. Immunotherapy
    • 15.2.3. Chemotherapy
  • 15.3. Market Value Forecast, by Drug Type, 2017 - 2031
    • 15.3.1. Atezolizumab
    • 15.3.2. Durvalumab
    • 15.3.3. Lurbinectedin
    • 15.3.4. Pembrolizumab
    • 15.3.5. Etoposide
    • 15.3.6. Methotrexate
    • 15.3.7. Topotecan
    • 15.3.8. Others
  • 15.4. Market Value Forecast, by Route of Administration, 2017 - 2031
    • 15.4.1. Oral
    • 15.4.2. Parenteral
    • 15.4.3. Others
  • 15.5. Market Value Forecast, by Distribution Channel, 2017 - 2031
    • 15.5.1. Hospital Pharmacies
    • 15.5.2. Retail Pharmacies
    • 15.5.3. Online Pharmacies
  • 15.6. Market Value Forecast, by Country, 2017 - 2031
    • 15.6.1. GCC Countries
    • 15.6.2. South Africa
    • 15.6.3. Rest of Middle East & Africa
  • 15.7. Market Attractiveness Analysis
    • 15.7.1. By Therapy Type
    • 15.7.2. By Drug Type
    • 15.7.3. By Route of Administration
    • 15.7.4. By Distribution Channel
    • 15.7.5. By Country

16. Competition Landscape

  • 16.1. Market Player - Competition Matrix (By Tier and Size of companies)
  • 16.2. Market Share Analysis By Company (2021)
  • 16.3. Company Profiles
    • 16.3.1. AstraZeneca plc
      • 16.3.1.1. Company Overview (HQ, Business Segments, Employee Strength)
      • 16.3.1.2. Test Type Portfolio
      • 16.3.1.3. Financial Overview
      • 16.3.1.4. SWOT Analysis
      • 16.3.1.5. Strategic Overview
    • 16.3.2. Dr. Reddy's Laboratories, Inc.
      • 16.3.2.1. Company Overview (HQ, Business Segments, Employee Strength)
      • 16.3.2.2. Test Type Portfolio
      • 16.3.2.3. Financial Overview
      • 16.3.2.4. SWOT Analysis
      • 16.3.2.5. Strategic Overview
    • 16.3.3. F. Hoffmann La-Roche Ltd.
      • 16.3.3.1. Company Overview (HQ, Business Segments, Employee Strength)
      • 16.3.3.2. Test Type Portfolio
      • 16.3.3.3. Financial Overview
      • 16.3.3.4. SWOT Analysis
      • 16.3.3.5. Strategic Overview
    • 16.3.4. GSK plc
      • 16.3.4.1. Company Overview (HQ, Business Segments, Employee Strength)
      • 16.3.4.2. Test Type Portfolio
      • 16.3.4.3. Financial Overview
      • 16.3.4.4. SWOT Analysis
      • 16.3.4.5. Strategic Overview
    • 16.3.5. Jazz Pharmaceuticals plc
      • 16.3.5.1. Company Overview (HQ, Business Segments, Employee Strength)
      • 16.3.5.2. Test Type Portfolio
      • 16.3.5.3. Financial Overview
      • 16.3.5.4. SWOT Analysis
      • 16.3.5.5. Strategic Overview
    • 16.3.6. Merck & Co., Inc.
      • 16.3.6.1. Company Overview (HQ, Business Segments, Employee Strength)
      • 16.3.6.2. Test Type Portfolio
      • 16.3.6.3. Financial Overview
      • 16.3.6.4. SWOT Analysis
      • 16.3.6.5. Strategic Overview
    • 16.3.7. Novartis AG
      • 16.3.7.1. Company Overview (HQ, Business Segments, Employee Strength)
      • 16.3.7.2. Test Type Portfolio
      • 16.3.7.3. Financial Overview
      • 16.3.7.4. SWOT Analysis
      • 16.3.7.5. Strategic Overview
    • 16.3.8. Pfizer Inc.
      • 16.3.8.1. Company Overview (HQ, Business Segments, Employee Strength)
      • 16.3.8.2. Test Type Portfolio
      • 16.3.8.3. Financial Overview
      • 16.3.8.4. SWOT Analysis
      • 16.3.8.5. Strategic Overview

List of Tables

  • Table 01: Global Small Cell Lung Cancer (SCLC) Therapeutics Market Value (US$ Mn) Forecast, by Therapy Type, 2017-2031
  • Table 02: Global Small Cell Lung Cancer (SCLC) Therapeutics Market Value (US$ Mn) Forecast, by Drug Type, 2017-2031
  • Table 03: Global Small Cell Lung Cancer (SCLC) Therapeutics Market Value (US$ Mn) Forecast, by Route of Administration, 2017-2031
  • Table 04: Global Small Cell Lung Cancer (SCLC) Therapeutics Market Value (US$ Mn) Forecast, by Distribution Channel, 2017-2031
  • Table 05: Global Small Cell Lung Cancer (SCLC) Therapeutics Market Value (US$ Mn) Forecast, by Region, 2017-2031
  • Table 06: Asia Pacific Small Cell Lung Cancer (SCLC) Therapeutics Market Value (US$ Mn) Forecast, by Country, 2017-2031
  • Table 06: North America Small Cell Lung Cancer (SCLC) Therapeutics Market Value (US$ Mn) Forecast, by Country, 2017-2031
  • Table 07: North America Small Cell Lung Cancer (SCLC) Therapeutics Market Value (US$ Mn) Forecast, by Therapy Type, 2017-2031
  • Table 08: North America Small Cell Lung Cancer (SCLC) Therapeutics Market Value (US$ Mn) Forecast, by Drug Type, 2017-2031
  • Table 09: North America Small Cell Lung Cancer (SCLC) Therapeutics Market Value (US$ Mn) Forecast, by Route of Administration, 2017-2031
  • Table 10: North America Small Cell Lung Cancer (SCLC) Therapeutics Market Value (US$ Mn) Forecast, by Distribution Channel, 2017-2031
  • Table 11: Europe Small Cell Lung Cancer (SCLC) Therapeutics Market Value (US$ Mn) Forecast, by Country, 2017-2031
  • Table 12: Europe Small Cell Lung Cancer (SCLC) Therapeutics Market Value (US$ Mn) Forecast, by Therapy Type, 2017-2031
  • Table 13: Europe Small Cell Lung Cancer (SCLC) Therapeutics Market Value (US$ Mn) Forecast, by Drug Type, 2017-2031
  • Table 14: Europe Small Cell Lung Cancer (SCLC) Therapeutics Market Value (US$ Mn) Forecast, by Route of Administration, 2017-2031
  • Table 15: Europe Small Cell Lung Cancer (SCLC) Therapeutics Market Value (US$ Mn) Forecast, by Distribution Channel, 2017-2031
  • Table 17: Asia Pacific Small Cell Lung Cancer (SCLC) Therapeutics Market Value (US$ Mn) Forecast, by Therapy Type, 2017-2031
  • Table 18: Asia Pacific Small Cell Lung Cancer (SCLC) Therapeutics Market Value (US$ Mn) Forecast, by Drug Type, 2017-2031
  • Table 19: Asia Pacific Small Cell Lung Cancer (SCLC) Therapeutics Market Value (US$ Mn) Forecast, by Route of Administration, 2017-2031
  • Table 20: Asia Pacific Small Cell Lung Cancer (SCLC) Therapeutics Market Value (US$ Mn) Forecast, by Distribution Channel, 2017-2031
  • Table 21: Latin America Small Cell Lung Cancer (SCLC) Therapeutics Market Value (US$ Mn) Forecast, by Country, 2017-2031
  • Table 22: Latin America Small Cell Lung Cancer (SCLC) Therapeutics Market Value (US$ Mn) Forecast, by Therapy Type, 2017-2031
  • Table 23: Latin America Small Cell Lung Cancer (SCLC) Therapeutics Market Value (US$ Mn) Forecast, by Drug Type, 2017-2031
  • Table 24: Latin America Small Cell Lung Cancer (SCLC) Therapeutics Market Value (US$ Mn) Forecast, by Route of Administration, 2017-2031
  • Table 25: Latin America Small Cell Lung Cancer (SCLC) Therapeutics Market Value (US$ Mn) Forecast, by Distribution Channel, 2017-2031
  • Table 26: Middle East & Africa Small Cell Lung Cancer (SCLC) Therapeutics Market Value (US$ Mn) Forecast, by Country, 2017-2031
  • Table 27: Middle East & Africa Small Cell Lung Cancer (SCLC) Therapeutics Market Value (US$ Mn) Forecast, by Therapy Type, 2017-2031
  • Table 28: Middle East & Africa Small Cell Lung Cancer (SCLC) Therapeutics Market Value (US$ Mn) Forecast, by Drug Type, 2017-2031
  • Table 29: Middle East & Africa Small Cell Lung Cancer (SCLC) Therapeutics Market Value (US$ Mn) Forecast, by Route of Administration, 2017-2031
  • Table 30: Middle East & Africa Small Cell Lung Cancer (SCLC) Therapeutics Market Value (US$ Mn) Forecast, by Distribution Channel, 2017-2031

List of Figures

  • Figure 01: Global Small Cell Lung Cancer (SCLC) Therapeutics Market Value (US$ Mn) Forecast, 2017-2031
  • Figure 02: Small Cell Lung Cancer (SCLC) Therapeutics Market Value Share, by Therapy Type, 2022
  • Figure 03: Small Cell Lung Cancer (SCLC) Therapeutics Market Value Share, by Drug Type, 2022
  • Figure 04: Small Cell Lung Cancer (SCLC) Therapeutics Market Value Share, by Route of Administration, 2022
  • Figure 05: Small Cell Lung Cancer (SCLC) Therapeutics Market Value Share, by Distribution Channel, 2022
  • Figure 06: Global Small Cell Lung Cancer (SCLC) Therapeutics Market Value Share Analysis, by Therapy Type, 2022 and 2031
  • Figure 07: Global Small Cell Lung Cancer (SCLC) Therapeutics Market Attractiveness Analysis, by Therapy Type, 2023-2031
  • Figure 08: Global Small Cell Lung Cancer (SCLC) Therapeutics Market (US$ Mn), by Targeted Therapy, 2017-2031
  • Figure 09: Global Small Cell Lung Cancer (SCLC) Therapeutics Market (US$ Mn), by Immunotherapy, 2017-2031
  • Figure 10: Global Small Cell Lung Cancer (SCLC) Therapeutics Market (US$ Mn), by Chemotherapy, 2017-2031
  • Figure 11: Global Small Cell Lung Cancer (SCLC) Therapeutics Market Value Share Analysis, by Drug Type, 2022 and 2031
  • Figure 12: Global Small Cell Lung Cancer (SCLC) Therapeutics Market Attractiveness Analysis, by Drug Type, 2023-2031
  • Figure 13: Global Small Cell Lung Cancer (SCLC) Therapeutics Market (US$ Mn), by Atezolizumab, 2017-2031
  • Figure 14: Global Small Cell Lung Cancer (SCLC) Therapeutics Market (US$ Mn), by Durvalumab, 2017-2031
  • Figure 15: Global Small Cell Lung Cancer (SCLC) Therapeutics Market (US$ Mn), by Lurbinectedin, 2017-2031
  • Figure 16: Global Small Cell Lung Cancer (SCLC) Therapeutics Market (US$ Mn), by Pembrolizumab, 2017-2031
  • Figure 17: Global Small Cell Lung Cancer (SCLC) Therapeutics Market (US$ Mn), by Etoposide, 2017-2031
  • Figure 18: Global Small Cell Lung Cancer (SCLC) Therapeutics Market (US$ Mn), by Methotrexate, 2017-2031
  • Figure 19: Global Small Cell Lung Cancer (SCLC) Therapeutics Market (US$ Mn), by Topotecan, 2017-2031
  • Figure 20: Global Small Cell Lung Cancer (SCLC) Therapeutics Market (US$ Mn), by Others, 2017-2031
  • Figure 21: Global Small Cell Lung Cancer (SCLC) Therapeutics Market Value Share Analysis, by Route of Administration, 2022 and 2031
  • Figure 22: Global Small Cell Lung Cancer (SCLC) Therapeutics Market Attractiveness Analysis, by Route of Administration, 2023-2031
  • Figure 23: Global Small Cell Lung Cancer (SCLC) Therapeutics Market (US$ Mn), by Oral, 2017-2031
  • Figure 24: Global Small Cell Lung Cancer (SCLC) Therapeutics Market (US$ Mn), by Parenteral, 2017-2031
  • Figure 25: Global Small Cell Lung Cancer (SCLC) Therapeutics Market (US$ Mn), by Others, 2017-2031
  • Figure 26: Global Small Cell Lung Cancer (SCLC) Therapeutics Market Value Share Analysis, by Distribution Channel, 2022 and 2031
  • Figure 27: Global Small Cell Lung Cancer (SCLC) Therapeutics Market Attractiveness Analysis, by Distribution Channel, 2023-2031
  • Figure 28: Global Small Cell Lung Cancer (SCLC) Therapeutics Market (US$ Mn), by Hospital Pharmacies, 2017-2031
  • Figure 29: Global Small Cell Lung Cancer (SCLC) Therapeutics Market (US$ Mn), by Retail Pharmacies, 2017-2031
  • Figure 30: Global Small Cell Lung Cancer (SCLC) Therapeutics Market (US$ Mn), by Online Pharmacies, 2017-2031
  • Figure 31: Global Small Cell Lung Cancer (SCLC) Therapeutics Market Value Share Analysis, by Region, 2022 and 2031
  • Figure 32: Global Small Cell Lung Cancer (SCLC) Therapeutics Market Attractiveness Analysis, by Region, 2023-2031
  • Figure 33: North America Small Cell Lung Cancer (SCLC) Therapeutics Market Value (US$ Mn) Forecast, 2017-2031
  • Figure 34: North America Small Cell Lung Cancer (SCLC) Therapeutics Market Value Share Analysis, by Country, 2022 and 2031
  • Figure 35: North America Small Cell Lung Cancer (SCLC) Therapeutics Market Attractiveness Analysis, by Country, 2023-2031
  • Figure 36: North America Small Cell Lung Cancer (SCLC) Therapeutics Market Value Share Analysis, by Therapy Type, 2022 and 2031
  • Figure 37: North America Small Cell Lung Cancer (SCLC) Therapeutics Market Attractiveness Analysis, by Therapy Type, 2023-2031
  • Figure 38: North America Small Cell Lung Cancer (SCLC) Therapeutics Market Value Share Analysis, by Drug Type, 2022 and 2031
  • Figure 39: North America Small Cell Lung Cancer (SCLC) Therapeutics Market Attractiveness Analysis, by Drug Type, 2023-2031
  • Figure 40: North America Small Cell Lung Cancer (SCLC) Therapeutics Market Value Share Analysis, by Route of Administration, 2022 and 2031
  • Figure 41: North America Small Cell Lung Cancer (SCLC) Therapeutics Market Attractiveness Analysis, by Route of Administration, 2023-2031
  • Figure 42: North America Small Cell Lung Cancer (SCLC) Therapeutics Market Value Share Analysis, by Distribution Channel, 2022 and 2031
  • Figure 43: North America Small Cell Lung Cancer (SCLC) Therapeutics Market Attractiveness Analysis, by Distribution Channel, 2023-2031
  • Figure 44: Europe Small Cell Lung Cancer (SCLC) Therapeutics Market Value (US$ Mn) Forecast, 2017-2031
  • Figure 45: Europe Small Cell Lung Cancer (SCLC) Therapeutics Market Value Share Analysis, by Country, 2022 and 2031
  • Figure 46: Europe Small Cell Lung Cancer (SCLC) Therapeutics Market Attractiveness Analysis, by Country, 2023-2031
  • Figure 47: Europe Small Cell Lung Cancer (SCLC) Therapeutics Market Value Share Analysis, by Therapy Type, 2022 and 2031
  • Figure 48: Europe Small Cell Lung Cancer (SCLC) Therapeutics Market Attractiveness Analysis, by Therapy Type, 2023-2031
  • Figure 49: Europe Small Cell Lung Cancer (SCLC) Therapeutics Market Value Share Analysis, by Drug Type, 2022 and 2031
  • Figure 50: Europe Small Cell Lung Cancer (SCLC) Therapeutics Market Attractiveness Analysis, by Drug Type, 2023-2031
  • Figure 51: Europe Small Cell Lung Cancer (SCLC) Therapeutics Market Value Share Analysis, by Route of Administration, 2022 and 2031
  • Figure 52: Europe Small Cell Lung Cancer (SCLC) Therapeutics Market Attractiveness Analysis, by Route of Administration, 2023-2031
  • Figure 53: Europe Small Cell Lung Cancer (SCLC) Therapeutics Market Value Share Analysis, by Distribution Channel, 2022 and 2031
  • Figure 54: Europe Small Cell Lung Cancer (SCLC) Therapeutics Market Attractiveness Analysis, by Distribution Channel, 2023-2031
  • Figure 55: Asia Pacific Small Cell Lung Cancer (SCLC) Therapeutics Market Value (US$ Mn) Forecast, 2017-2031
  • Figure 56: Asia Pacific Small Cell Lung Cancer (SCLC) Therapeutics Market Value Share Analysis, by Country, 2022 and 2031
  • Figure 57: Asia Pacific Small Cell Lung Cancer (SCLC) Therapeutics Market Attractiveness Analysis, by Country, 2023-2031
  • Figure 58: Asia Pacific Small Cell Lung Cancer (SCLC) Therapeutics Market Value Share Analysis, by Therapy Type, 2022 and 2031
  • Figure 59: Asia Pacific Small Cell Lung Cancer (SCLC) Therapeutics Market Attractiveness Analysis, by Therapy Type, 2023-2031
  • Figure 60: Asia Pacific Small Cell Lung Cancer (SCLC) Therapeutics Market Value Share Analysis, by Drug Type, 2022 and 2031
  • Figure 61: Asia Pacific Small Cell Lung Cancer (SCLC) Therapeutics Market Attractiveness Analysis, by Drug Type, 2023-2031
  • Figure 62: Asia Pacific Small Cell Lung Cancer (SCLC) Therapeutics Market Value Share Analysis, by Route of Administration, 2022 and 2031
  • Figure 63: Asia Pacific Small Cell Lung Cancer (SCLC) Therapeutics Market Attractiveness Analysis, by Route of Administration, 2023-2031
  • Figure 64: Asia Pacific Small Cell Lung Cancer (SCLC) Therapeutics Market Value Share Analysis, by Distribution Channel, 2022 and 2031
  • Figure 65: Asia Pacific Small Cell Lung Cancer (SCLC) Therapeutics Market Attractiveness Analysis, by Distribution Channel, 2023-2031
  • Figure 65: Latin America Small Cell Lung Cancer (SCLC) Therapeutics Market Value (US$ Mn) Forecast, 2017-2031
  • Figure 67: Latin America Small Cell Lung Cancer (SCLC) Therapeutics Market Value Share Analysis, by Country, 2022 and 2031
  • Figure 68: Latin America Small Cell Lung Cancer (SCLC) Therapeutics Market Attractiveness Analysis, by Country, 2023-2031
  • Figure 69: Latin America Small Cell Lung Cancer (SCLC) Therapeutics Market Value Share Analysis, by Therapy Type, 2022 and 2031
  • Figure 70: Latin America Small Cell Lung Cancer (SCLC) Therapeutics Market Attractiveness Analysis, by Therapy Type, 2023-2031
  • Figure 71: Latin America Small Cell Lung Cancer (SCLC) Therapeutics Market Attractiveness Analysis, by Drug Type, 2023-2031
  • Figure 71: Latin America Small Cell Lung Cancer (SCLC) Therapeutics Market Value Share Analysis, by Drug Type, 2022 and 2031
  • Figure 73: Latin America Small Cell Lung Cancer (SCLC) Therapeutics Market Value Share Analysis, by Route of Administration, 2022 and 2031
  • Figure 74: Latin America Small Cell Lung Cancer (SCLC) Therapeutics Market Attractiveness Analysis, by Route of Administration, 2023-2031
  • Figure 75: Latin America Small Cell Lung Cancer (SCLC) Therapeutics Market Value Share Analysis, by Distribution Channel, 2022 and 2031
  • Figure 76: Latin America Small Cell Lung Cancer (SCLC) Therapeutics Market Attractiveness Analysis, by Distribution Channel, 2023-2031
  • Figure 77: Middle East & Africa Small Cell Lung Cancer (SCLC) Therapeutics Market Value (US$ Mn) Forecast, 2017-2031
  • Figure 78: Middle East & Africa Small Cell Lung Cancer (SCLC) Therapeutics Market Value Share Analysis, by Country, 2022 and 2031
  • Figure 79: Middle East & Africa Small Cell Lung Cancer (SCLC) Therapeutics Market Attractiveness Analysis, by Country, 2023-2031
  • Figure 80: Middle East & Africa Small Cell Lung Cancer (SCLC) Therapeutics Market Value Share Analysis, by Therapy Type, 2022 and 2031
  • Figure 81: Middle East & Africa Small Cell Lung Cancer (SCLC) Therapeutics Market Attractiveness Analysis, by Therapy Type, 2023-2031
  • Figure 82: Middle East & Africa Small Cell Lung Cancer (SCLC) Therapeutics Market Value Share Analysis, by Drug Type, 2022 and 2031
  • Figure 83: Middle East & Africa Small Cell Lung Cancer (SCLC) Therapeutics Market Attractiveness Analysis, by Drug Type, 2023-2031
  • Figure 84: Middle East & Africa Small Cell Lung Cancer (SCLC) Therapeutics Market Value Share Analysis, by Route of Administration, 2022 and 2031
  • Figure 85: Middle East & Africa Small Cell Lung Cancer (SCLC) Therapeutics Market Attractiveness Analysis, by Route of Administration, 2023-2031
  • Figure 86: Middle East & Africa Small Cell Lung Cancer (SCLC) Therapeutics Market Value Share Analysis, by Distribution Channel, 2022 and 2031
  • Figure 87: Middle East & Africa Small Cell Lung Cancer (SCLC) Therapeutics Market Attractiveness Analysis, by Distribution Channel, 2023-2031
  • Figure 88: Global Small Cell Lung Cancer (SCLC) Therapeutics Market Share Analysis, by Company, 2022